reports
1369 Construction JSC: 1 director
A director at 1369 Construction JSC bought 300,000 shares at 0.000VND and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Wolters Kluwer unveils AI center; Provides direct access to its AI-dri...
Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise PRESS RELEASE Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise Alphen aan den Rijn – May 6, 2024 – Wolters Kluwer, a global leader in professional information, software solutions, and services, today unveiled its dedicated . The launch marks the company's ongoing commitment to combining deep domain knowledge with cutting-edge technology such as artificial intelligence (AI), which Wolters Kluwer has been incorporating into ...
Lincoln Educational Services Reports Continued Growth During First Qua...
Lincoln Educational Services Reports Continued Growth During First Quarter 2024, with 15% Student Starts and 20% Revenue Growth; Increasing Financial Guidance for Full Year 2024 Conference Call Today at 10 a.m. ET PARSIPPANY, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corporation (Nasdaq: LINC) today announced financial and operating results for the first quarter ended March 31, 2024, as well as recent business developments. First Quarter 2024 Financial Highlights* Revenue grew 19.7% to $103.4 millionAdjusted EBITDA tripled to $6.5 millionStudent starts in...
Hanmi Bank Celebrates Grand Opening of its New Fort Lee, New Jersey Br...
Hanmi Bank Celebrates Grand Opening of its New Fort Lee, New Jersey Branch with Local Community LOS ANGELES, May 06, 2024 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (Nasdaq: HAFC) (“Hanmi”), the holding company for Hanmi Bank, today announced it hosted a community grand opening event on May 2 to commemorate its new branch in Fort Lee, NJ. Clients of the bank and local leaders including Assemblywoman Ellen J. Park, Fort Lee Mayor Mark J. Sokolich, and Councilman Paul K. Yoon joined the celebration. The 3,500 square foot branch is located at 1605 Lemoine Ave, Fort Lee, NJ. The new bra...
Infinera Provides Update on the Expected Filing of its Fiscal 2023 For...
Infinera Provides Update on the Expected Filing of its Fiscal 2023 Form 10-K SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Infinera Corporation (NASDAQ: INFN) announced today that it expects to file its fiscal year 2023 Annual Report on Form 10-K on or before May 13, 2024. The company, along with its auditors, is continuing to make progress with the normal year-end close process. The company also announced that it expects to release its financial results for the first quarter of fiscal 2024 and outlook for the second quarter of fiscal 2024, after the market closes on May 14, 2024. A...
HEALWELL AI Announces $16 Million Bought Deal Private Placement
HEALWELL AI Announces $16 Million Bought Deal Private Placement NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. ("HEALWELL" or the "Company") (TSX: AIDX), a data science and AI company focused on preventative care, is pleased to announce that it has entered into an agreement pursuant to which Clarus Securities Inc. and Eight Capital, as lead underwriters and co-bookrunners, together with a syndicate of underwriters (collectively, the “Underwriters”), will purchase 11,851,900 units of th...
Buyuk Sefler Gida Turizm Tekstil Danismanlik Org. Egt. San. ve Tic AS:...
Six Directors at Buyuk Sefler Gida Turizm Tekstil Danismanlik Org. Egt. San. ve Tic AS sold/bought/maiden bought 10,101,263 shares at between 30.000TRY and 33.025TRY. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price...
Carlsberg AS: 2 directors
Two Directors at Carlsberg AS bought/sold 22,743 shares at between 928.680DKK and 936.580DKK. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results an...
Lyell Immunopharma Reports Business Highlights and Financial Results f...
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second half of 2024IND for second generation ROR1-targeted CAR T-cell product candidate on track for submission this quarterCash, cash equivalents and marketable securities of $526.3 million as of March 31, 2024 supports ...
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief ...
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. “We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in ...
Krystal Biotech Announces First Quarter 2024 Financial Results and Pro...
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track Designations for both inhaled and intratumoral KB707Strong balance sheet with $622.3 million in cash and investments PITTSBURGH, May 06, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the first qua...
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlareb...
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support for the potential of Tinlarebant to slow and potentially halt lesion growthIn 5 of 12 subjects (42%) with known pathogenic ABCA4 mutations, no incident atrophic (DDAF) lesions were formed during the 24-month treatment period and no change in QDAF was observedA novel lesion si...
PIRANHA Receives Unanimous Approval From Massachusetts Plumbing and Ga...
PIRANHA Receives Unanimous Approval From Massachusetts Plumbing and Gas Fitting Board for State Expansion VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Inc. () () () ("SHARC Energy" or the “Company”), a world leader in wastewater energy transfer (“WET”), is pleased to announce that it has received unanimous approval from the for ten PIRANHA pilot sites in the state. This pilot project aims to demonstrate the efficacy of WET across multiple sectors and building types. The Company's application to the Massachusetts Plumber and Gas Fitter Board garnered strong ba...
Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to As...
Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to Asia Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the sale of the first SRT-100 Vision™ (IG-SRT) system in Asia, to Far Eastern Memorial Hospital in Taiwan. The hospital, which has more than 1,000 beds, is one of the largest private ho...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City. Management will be holding one-on-one meetings with investors. About Processa Pharmace...
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Co...
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference. H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20th, 2024; NYC)Date/Time:May 20, 2024, 4:30 p.m. ETWebcast: The session will be webcast live and archived on the Company’s website in the I...
Akoya Biosciences Opens Operations and Manufacturing Center of Excelle...
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms. “Spatial biology is transforming drug discovery, translational sciences, and clinical research, and advancing our ability to un...
RYVYL to Announce First Quarter 2023 Financial Results on Tuesday, May...
RYVYL to Announce First Quarter 2023 Financial Results on Tuesday, May 14, 2024 SAN DIEGO, CA , May 06, 2024 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the "Company"), a leading innovator of payment transaction solutions leveraging proprietary blockchain ledger and electronic token technology for the diverse international markets, expects to report financial results for the first quarter 2024 on Tuesday, May 14, 2024. RYVYL management will host a conference call at 4:30 p.m. Eastern Time on Tuesday, May 14, 2024 to discuss the Company’s financial results for the first qu...
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN20...
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD trial expected to start this quarter BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.